Prolexys Pharmaceuticals, Inc. raised $20 million from an investment by Friedli Corporate Finance. The investment will allow for Prolexys Pharmaceuticals to continue research on a unique molecule called PRLX 93936.

PRLX 93936 is significant to multiple myeloma patients because of its vigorous and selective anti-tumor activity. The drug shows promising action in disease models such as those of multiple myeloma and other cancers with less medical treatments and options.

Currently, PRLX 93936 is in Phase 1 study, which examines drug aspects such as safety and possible side effects. PRLX 93936 is being administered in twenty-eight-day cycles to patients with advanced solid tumors. Tumor response is evaluated every other cycle. So far, fifteen patients have received treatment and six have undergone multiple cycles of treatment. As the study continues, delivered doses will produce drug exposure levels at which considerable anti-tumor activity has been observed in mouse models of human cancer. Comprehensively, the treatment appears to be well tolerated by patients.

At this stage in development and with such a large investment, Prolexys Pharmaceuticals is on its way to providing much-needed drugs and treatments to multiple myeloma patients and other cancer patients.